Rating Change
Leerink Partners analysts initiated coverage on ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) with a rating of Outperform on October 05, 2026.
new coverageNASDAQ:ORIC
Leerink Partners Initiates Coverage on ORIC Pharmaceuticals, Inc. (ORIC) with Outperform
Leerink Partners analysts initiated coverage on ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) with a rating of Outperform on October 05, 2026.
At publication ·
What changed
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) · new coverage
- Firm
- Leerink Partners
- Rating
- Outperform
- Price at event
- $12.49
- Market capitalization
- $944.7M
At a glance
Key takeaways
- Leerink Partners initiated coverage of ORIC Pharmaceuticals with an Outperform rating on October 5, 2026.
- ORIC trades at $12.49 with a market capitalization of $944.7 million.
Market Context
ORIC Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $12.49 with a market capitalization of $944.7M. The stock has gained 5.5% over the past 52 weeks.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ORIC Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ORIC Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 05, 2026 | Leerink Partners | Outperform | N/A |
| Sep 23, 2026 | BTIG | Buy | N/A |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 08, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 05, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ORIC Stock Page
Frequently Asked Questions
What does the Outperform rating mean for ORIC?
A rating of Outperform from Leerink Partners reflects the analyst's outlook on ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ORIC forecast page.